Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Latest News

Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy

Read More

Ligand and GSK Expand Global Collaboration and License Agreement

Read More

Ligand Reports Third Quarter 2021 Financial Results

Read More

Recent Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range